CDA | Evidence Driven
CDA | Evidence Driven

dapagliflozin

Details

Generic Name:
dapagliflozin
Project Status:
Not filed
Therapeutic Area:
Chronic kidney disease
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Forxiga
Project Line:
Reimbursement Review
Project Number:
NS0021-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
To reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease (CKD).
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024